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1Introduction
Fungal infections are a threat to hospitalized and im-
munocompromised patients. Candida albicans is a major 
common fungal pathogen in humans that colonizes the 
skin and the mucosal surfaces of most healthy individuals. 
Together with superficial infections, such as oral or vaginal 
candidiasis, a life- threatening systemic infection can even-
tually occur (Mayer et al. 2013). Candida albicans is the 
causative agent of most candidiasis, but other emerging 
species, such as Candida glabrata and Candida krusei, are 
also considered to be threats to patient populations. 
Candida infections have increased dramatically over the 
last two decades. Considering the increase in Candida 
pathogenesis, mostly in immunocompromised patients, 
but also in healthy individuals, active research has focused 
on new therapies and treatments. Several factors and 
 activities that contribute to the pathogenic potential of 
this fungus have been identified. As a first consideration, 
Candida albicans displays a complex cell wall organization 
that plays a role in maintaining structural integrity and 
mediating adherence. Its specific composition, which is 
predominantly composed of carbohydrates (Chitin, β- 1,3 
glucan, and β- 1,6 glucan), offers resistance to host mo-
lecular defense and is impermeable to most potential 
antifungal drugs (Molero et al. 1998; Mayer et al. 2013).
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Abstract
Human antimicrobial RNases, which belong to the vertebrate RNase A super-
family and are secreted upon infection, display a wide spectrum of antipathogen 
activities. In this work, we examined the antifungal activity of the eosinophil 
RNase 3 and the skin- derived RNase 7, two proteins expressed by innate cell 
types that are directly involved in the host defense against fungal infection. 
Candida albicans has been selected as a suitable working model for testing 
RNase activities toward a eukaryotic pathogen. We explored the distinct levels 
of action of both RNases on yeast by combining cell viability and membrane 
model assays together with protein labeling and confocal microscopy. Site- directed 
mutagenesis was applied to ablate either the protein active site or the key an-
choring region for cell binding. This is the first integrated study that highlights 
the RNases’ dual mechanism of action. Along with an overall membrane- 
destabilization process, the RNases could internalize and target cellular RNA. 
The data support the contribution of the enzymatic activity for the antipathogen 
action of both antimicrobial proteins, which can be envisaged as suitable tem-
plates for the development of novel antifungal drugs. We suggest that both 
human RNases work as multitasking antimicrobial proteins that provide a first 
line immune barrier.
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Knowledge of pathogenicity mechanisms, ranging from 
cell wall complexity to the adhesion and host cell inva-
sion mechanism (Chaffin 2008), is crucial for the rational 
design of novel antifungal drugs (Molero et al. 1998; 
Mayer et al. 2013). Antimicrobial peptides (AMPs) and 
in particular, those secreted by the human skin, our 
first natural barrier against infections, are regarded as 
appealing candidates for applied antifungal therapy (den 
Hertog et al. 2005; Vylkova et al. 2007; Andrès 2012). 
Indeed, AMPs offer a chemical defense system that pro-
tects the skin from potential pathogenic microorganisms 
threatening to colonize host tissues (Harder and Schroder 
2002; Bardan et al. 2004; Gläser et al. 2005). Among 
skin AMPs, there are peptides with reported antifungal 
activity, such as cathelicidins (López- García et al. 2005) 
and defensins (De Smet and Contreras 2005). Both pep-
tides are rapidly released at high local concentrations 
when needed in response to infection or epidermal injury 
(Dorschner et al. 2001; Niyonsaba and Ogawa 2005; 
Sørensen et al. 2006). Moreover, the constant level of 
some constitutively produced antimicrobial peptides and 
proteins at skin surfaces suggests that these AMPs have 
been optimized during evolution to protect the skin 
surface from infection (Schröder and Harder 2006). In 
particular, human RNase 7 is one of the main products 
that is constitutively released by keratinocytes (Schröder 
and Harder 2006). RNase 7 not only has a well- 
documented bactericidal activity (Harder and Schroder 
2002; Torrent et al. 2010a; Pulido et al. 2013b) but also 
inhibits the growth of yeast (Harder and Schroder 2002; 
Huang et al. 2007) and dermatophytes (Fritz et al. 2012).
Interestingly, RNase 7 is a member of the RNase A 
superfamily (Fig. 1). This family, which includes other se-
cretory RNases with antimicrobial properties (Boix and 
Nogués 2007), is a protein family that is suggested to have 
emerged with an ancestral host defense role (Pizzo and 
D’Alessio 2007; Rosenberg 2008). Antimicrobial RNases are 
expressed by epithelial tissues and blood cell types, and 
their expression can be induced by inflammatory agents 
and bacterial infection (Gupta et al. 2012; Spencer et al. 
2013; Amatngalim et al. 2015; Becknell et al. 2015). In 
particular, RNase 3 and RNase 7 are the main representa-
tive members that show a high bactericidal activity (Torrent 
et al. 2010a, 2012; Pulido et al. 2013b). RNase 7 is expressed 
in the skin- derived stratum, the gut, and the respiratory 
and genitourinary tracts (Spencer et al. 2013; Becknell et al. 
2015) and is particularly active against both gram- negative 
and gram- positive species, such as Enterococcus faecium, 
Pseudomonas aeruginosa, and Escherichia coli (Harder and 
Schroder 2002; Huang et al. 2007; Torrent et al. 2010a).
On its turn, RNase 3, another of the main antimicrobial 
RNases within the RNase A superfamily (Fig. 1), also 
called the Eosinophil Cationic Protein (ECP), is involved 
in inflammatory processes mediated by eosinophils and 
is released by the secondary granules upon infection 
(Acharya and Ackerman 2014). RNase 3 has also been 
reported to display high antimicrobial activity against both 
gram- negative bacteria, such as E. coli, Acinetobacter bau-
mannii, and Pseudomonas sp. (Torrent et al. 2011b), and 
gram- positive species, such as Staphylococcus aureus, 
Micrococcus luteus, and E. faecium, (Torrent et al. 2011b) 
as well as Mycobacteria (Pulido et al. 2013b).
In this work, we explored the antifungal properties of 
both RNase 3 and 7. We used C. albicans as a eukaryotic 
pathogen model, which has proven to be an appropriate 
first approach to understand the distinct levels of action 
of antimicrobial RNases.
Experimental Procedures
Protein expression and purification
Recombinant RNase 3 and RNase 7 were expressed in E. 
coli BL21 (DE3) using the pET11c plasmid vector as pre-
viously described (Torrent et al. 2009). Protein expression, 
solubilization from inclusion bodies, refolding, and puri-
fication steps were carried out as described (Boix et al. 
1999). RNase 3- H15A, RNase 3- W35A, and RNase 7- H15A 
variants were constructed using the Quick Change Site- 
Directed Mutagenesis kit (Stratagene, La Jolla, CA). All 
constructs were confirmed by DNA sequencing and the 
purified protein was analyzed by MALDI- TOF MS and 
N- terminal sequencing.
Crystal structure determination
Recombinant protein was purified by cation exchange and 
reverse phase chromatographies as previously described 
(Boix et al. 2012a). RNase 3- H15A mutant was crystallized 
following the conditions for wild- type RNase 3 modified 
from (Mallorquí- Fernández et al. 2000). Protein sample 
was lyophilized and resuspended at 12 mg/mL in 20 mmol/L 
sodium cacodylate pH 5.0 and equilibrated against 7% 
Jeffamine™ M- 600, 0.1 mol/L Na citrate, pH 5.2, 10 mmol/L 
FeCl3. One microliter of the sample was mixed with an 
equal volume of the reservoir solution and set to incuba-
tion at 20°C. After 5 to 10 days, crystals appeared and 
were soaked using 30% methyl pentanediol as cryofreezing 
agent. Data were captured at 100 K using a λXRD = 0.9795 Å 
at the BL13 beamline of the ALBA Synchrotron Light Facility 
(Spain). XDS (Kabsch, 2010) was used for data processing. 
Scaling was performed with SCALA and molecular replace-
ment with PHASER (McCoy et al., 2007) using as a model 
the RNase 7 NMR structure (PDB coordinate file 2HKY 
(Huang et al. 2007)). Iterative cycles of refinement and 
manual structure fitting were performed with PHENIX 
3© 2016 The Authors. MicrobiologyOpen published by John Wiley & Sons Ltd. 
Antifungal Activity of Human RNasesV. A. Salazar et al.
(Adams et al., 2010) and COOT (Emsley and Cowtan, 
2004) until Rfree could not be further improved (Brunger, 
1992). Finally, the stereochemistry of the structure was 
validated with SFCHECK (Vaguine et al., 1999). Table S1 
shows all the data collection and structure refinement sta-
tistics. Solvent accessible surface areas for protein residues 
were calculated using the Areaimol software (The CCP4 
suite: programs for protein crystallography, 1994).
Figure 1. (A) Sequence alignment of RNase 3 and RNase 7. Primary sequences (UniProt codes: P12724 and Q9H1E1) were used, respectively. RNase 
3 three- dimensional structure is indicated (PDB ID: 4OXF). Cationic residues are shown in both proteins in green and fuchsia boxes, respectively. The 
alignment was performed using the ESPript program (http://espript.ibcp.fr/EsPript/). (B) Three dimensional representation of crystal structures of wild- 
type RNase 3 (yellow; PDB ID: 4OXF) and active site mutant RNase 3- H15A (purple; PDB ID: 4OWZ). Mutated residues (His 15 and Trp 35) are depicted 
in baton sticks. (C) Detail of active centre in both proteins. Picture was drawn with PyMOL Molecular Graphics System (Schrödinger, LLC).
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Enzymatic activity analysis
The RNases enzymatic activities of RNase 3, RNase 7, 
and active site mutants were measured spectrophotometri-
cally by registering the degradation of the oligocytidylic 
acid (Cp)4C>p at 286 nm in a Cary Eclipse spectropho-
tometer. The (Cp)4C>p acid, purified from poly(C), was 
used as a substrate, as previously described (Boix et al. 
1999). Assay conditions were 1 μmol/L protein, 84 μmol/L 
oligocytidylic acid in 0.2 mol/L NaAcO, pH 5.0, 3 min 
incubation time, and 25°C. Alternatively, a zymogram 
analysis was performed using a 15% SDS- PAGE gel con-
taining polyuridylic acid, poly(U), as a substrate according 
to the method previously described (Bravo et al. 1994).
Model membrane leakage activity
Membrane leakage activity was assessed by ANTS/DPX (8
- aminonaphthalene- 1,3,6- trisulfonic acid disodium salt/ 
p- xylenebispyridinium bromide) as previously (Torrent et al. 
2007). Large unilamellar vesicles of dioleoyl- phosphatidyl 
choline: dioleoyl- phosphatidyl glycerol (3:2 molar ratio), 
containing 12.5 mmol/L ANTS and 45 mmol/L DPX in 
20 mmol/L NaCl, 10 mmol/L Tris/HCl, pH 7.5, were  diluted 
to 30 μmol/L and incubated at 25°C with the proteins for 
45 min. Leakage was monitored as the increase in fluo-
rescence (λexcitation = 386 nm; λemission = 535 nm).
Fluorescent labeling of RNases
RNase 3, RNase 3- H15A, RNase 3- W35A, RNase 7- H15A, 
and RNase 7 were labeled with Alexa Fluor 488 Labeling 
kit (Molecular Probes, Invitrogen, Carlsbad, CA), following 
the manufacturer′s instruction as previously described 
(Torrent et al. 2010a). To 0.5 mL of 2 mg/mL protein 
solution in phosphate saline buffer (PBS), 50 μL of 1 mol/L 
sodium bicarbonate, pH 8.3, was added. The protein was 
incubated for 1 h at room temperature with the reactive 
dye, with stirring, and the labeled protein was separated 
from the free dye by PD- 10 desalting column.
Candida albicans growth conditions
Candida albicans (ATCC 90028) cells were maintained at 
−70°C and incubated overnight with agitation at 37°C in 
Sabouraud Dextrose broth (mycological peptone, glucose, 
pH 5.6) Fluka- Sigma S3306. Previous to each assay, cells 
were subcultured for ~2–3 h to yield a midlogarithmic 
culture.
Minimum fungicidal concentration
Candida albicans ATCC 90028 was cultured overnight in 
Sabouraud Dextrose broth at 37°C and subcultured the 
next day in fresh Sabouraud and grow to an optical den-
sity of 0.4 at 600 nm (mid log- phase). Cells were washed 
twice in nutrient broth or PBS, and diluted to 
~2 × 106 cells/mL. Proteins serially diluted were added 
to 2 × 105 cells from 20 to 0.1 μmol/L final concentra-
tion. Candida albicans was incubated at 37°C during 4 h 
in Sabouraud nutrient broth, PBS or 10 mmol/L sodium 
phosphate buffer, pH 7.5. Following, the samples were 
plated onto Sabouraud Petri dishes and incubated at 37°C 
overnight. Antifungal activity was expressed as the MFC, 
defined as the lowest protein concentration required for 
more than 99% of microorganism killing. MFC of each 
protein was determined from two independent experiments 
performed in triplicate for each concentration.
Cell viability assay
Antimicrobial activity was also assayed by following the 
cell viability of C. albicans, using the BacTiter- Glo™ 
Microbial Cell Viability kit (Promega, Madison, WI), which 
measures the number of viable fungal cells, by ATP quan-
tification. ATP, as an indicator of metabolically active 
cells, is indirectly measured by a coupled luminescence 
detection assay. The luminescent signal is proportional 
to the amount of ATP required for the conversion of 
luciferin into oxyluciferin in the presence of luciferase.
An overnight culture of C. albicans was used to inoculate 
fresh Sabouraud liquid culture, and logarithmic phase 
culture was grown to an OD600 of 0.2. RNase 3, RNase 
7, and mutants were added to 0.1 mL of cell culture at 
a final concentration from 0.025 to 20 μmol/L. The C. 
albicans viability was followed after 4 h of incubation at 
37°C. 50 μL of incubation culture was mixed with 50 μL 
of BacTiter- Glo™ reagent in a microtiter plate following 
the manufacturer instructions and incubated at room 
temperature for 10 min. Luminescence was read on a 
Victor3 plate reader (PerkinElmer, Waltham, MA) with 
a 1- s integration time. IC50 values were calculated by 
fitting the data to a dose–response curve.
Cell survival assay
Candida albicans viability assay was performed using the 
Live⁄Dead® microbial viability kit as previously described 
(Torrent et al. 2010a). Candida strain was grown at 37°C 
to ~5 × 106 cells/mL, centrifuged at 5000 × g for 5 min 
and resuspended in a 0.85% NaCl solution, in accordance 
with the manufacturer instructions. Candida albicans cell 
culture was stained using a SYTO®9/propidium iodide 1:1 
mixture. SYTO®9 is a DNA green fluorescent dye that 
diffuses thorough intact cell membranes and propidium 
iodide is a DNA red fluorescent dye that can only access 
the nucleic acids of membrane damaged cells, displacing 
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the DNA bound SYTO®9. The method allows the labeling 
of intact viable cells and membrane compromised cells, 
which are labeled in green and red, respectively, referred 
to as live and dead cells. The viability kinetics was moni-
tored using a Cary Eclipse Spectrofluorimeter (Varian Inc., 
Palo Alto, CA). Cell viability profiles were registered after 
adding from 1 to 5 μmol/L of final protein concentration. 
To calculate the cell viability, the fluorescence in the range 
of 510–540 nm and 620–650 nm were integrated to obtain 
the SYTO®9 (live cell) and the propidium iodide (dead 
cell) signals, respectively. Then, the percentage of live bac-
teria was represented as a function of time.
Cell viability by confocal microscopy
The kinetics of C. albicans survival was followed by confo-
cal microscopy for 180 min at 37°C. Experiments were 
carried out in a plate- coverslide system. Two hundred and 
fifty microliters of C. albicans ~ 4 × 106 cells/mL were 
stained as described below and mixed with the protein at 
5 μmol/L final concentration. Candida albicans cell cultures 
were prestained using the SYTO®9⁄propidium iodide 1:1 
mixture provided in the Live ⁄Dead® staining kit (Molecular 
Probes, Eugene, OR). Confocal images of the yeast culture 
were captured using a laser scanning confocal microscope 
(Leica TCS SP2 AOBS equipped with a HCX PL APO 
63, ×1.4 oil immersion objective; Leica Microsystems, 
Wetzlar, Germany). SYTO®9 was excited using a 488 nm 
argon laser (515–540 nm emission collected) and propidium 
iodide was excited using a diode pumped solid- state laser 
at 561 nm (588–715 nm emission collected). To record 
the time- lapse experiment, Life Data Mode software (Leica) 
was used, obtaining an image every minute.
Alternatively, labeled protein distribution in cell cultures 
was followed by confocal microscopy. 300 μL of Candida 
albicans yeast (~4 × 106 cell/mL) was incubated with Alexa- 
labeled proteins at 1 to 5 μmol/L during 1 h in PBS. Previously, 
cells were washed with PBS and labeled with Hoescht 33342 
at 0.5 μg/mL for 10 min before observation of unfixed cells 
in Leica TCS SP5 AOBS equipped with a PL APO 63 × 1.4- 
0.6 CS oil immersion objective (Leica Microsystems, Mannheim, 
Germany). Fluorochromes were excited by 405 nm (Hoechst 
33342) and 488 nm (Alexa Fluor 488 nm) and both emis-
sions collected with a HyD detector. Alexa Fluor 488- labeled 
proteins were added directly to the cultures and time lapse 
was recorded at intervals of 30 sec for 1 h.
Cell membrane depolarization assay
Membrane depolarization was assayed by monitoring the 
DiSC3(5) fluorescence intensity change in response to 
changes in transmembrane potential as described previ-
ously (Torrent et al. 2008). Candida albicans cells were 
grown at 37°C to the midexponential phase and resus-
pended in 5 mmol/L Hepes- KOH, 20 mmol/L glucose 
and 100 mmol/L KCl at pH 7.2. DiSC3(5) was added to 
a final concentration of 0.4 μmol/L. Changes in the fluo-
rescence for alteration of the cell plasma membrane 
 potential were continuously monitored at 20°C at an ex-
citation wavelength of 620 nm and an emission wavelength 
of 670 nm. When the dye uptake was maximal, as indicated 
by a stable reduction in the fluorescence as a result of 
quenching of the accumulated dye in the membrane in-
terior, protein in 5 mmol/L Hepes- KOH buffer at pH 7.2 
was added at a final protein concentration from 1 to 
5 μmol/L and incubated for 50 min. Maximum depolari-
zation was calculated when the fluorescence signal was 
fully stabilized and the depolarization percentage was cal-
culated taking Triton X- 100 at 10% as a positive control. 
The time required to reach a stabilized maximum fluo-
rescence reading was recorded for each condition, and the 
time required to achieve half of total membrane depo-
larization was estimated from the nonlinear regression 
curve. All conditions were assayed in duplicate.
Cell membrane permeabilization activity
Membrane permeabilization was evaluated by using the 
Sytox® Green uptake assay. Sytox® Green is a cationic 
cyanine dye (≈900 Da) that is not membrane permeable. 
When a cell’s plasma membrane integrity is compromised, 
influx of the dye, and subsequent binding to DNA, causes 
a large increase in the fluorescence signal. For Sytox® Green 
assays, Candida albicans cells were grown to midexponential 
growth phase at 37°C and then centrifuged, washed, and 
resuspended in PBS. Cell suspensions in PBS (~2 × 106 
cells/mL) were incubated with 1 μmol/L Sytox® Green for 
15 min in the dark prior to the influx assay. At 2 to 
4 min after initiating data collection, proteins at 1 and 
5 μmol/L final concentration were added to the cell sus-
pension, and the increase in Sytox® Green fluorescence 
was measured (excitation wavelength at 485 nm and emis-
sion at 520 nm) for 50 min in a Cary Eclipse spectro-
fluorimeter. Bacterial cell lysis with 10% Triton X- 100 
was taken as the maximum fluorescence reference value.
Cell binding assay
Candida albicans cells were cultured overnight in Sabouraud 
Dextrose broth at 37°C and subcultured the next day in 
fresh Sabouraud and grow to an optical density of 0.4 
at 600 nm (mid log- phase). Cells were washed twice in 
PBS, and diluted to ˜2 × 10
6 cells/mL. Cells were incu-
bated in 100 μL of PBS at 37°C with proteins at 1 μmol/L 
final concentration during different periods of time up 
to 1 h. Following, the samples were centrifugated at 
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13000 rpm. The supernatant samples were concentrated 
using 10 kDa cut- off filters to 20 μL. The presence of 
the proteins was checked by 15% SDS- PAGE and Coomassie 
Blue staining. Reference protein controls were treated fol-
lowing the same protocol in the absence of cells.
Fluorescent- assisted cell sorting (FACS) 
assay
The evolution of cell population was followed by cell cy-
tometry. Candida albicans cells were grown at 37°C to 
midexponential phase (~2 × 106 cells/mL), centrifuged at 
5000 × g for 2 min, resuspended in PBS. 500 μL aliquot 
of the yeast suspension was incubated with 1 to 5 μmol/L 
of Alexa- Fluor- labeled protein for 60 min. After incubation, 
25,000 cells were washed three times with PBS buffer and 
subjected to FACS analysis using a FACSCalibur cytometer 
(BD Biosciences, Franklin Lakes, NJ) and excitation and 
emission wavelengths of 488 nm and 515–545 nm, respec-
tively. Internal fluorescence uptake was evaluated at 2, 5, 
15, and 60 min in 10,000 cells. Dead cells were stained 
with PI dye added at a final concentration of 10 μg/mL.
Cellular RNA degradation
A C. albicans cell culture suspension (~6 × 106 cells/mL) 
was incubated in PBS and treated with the proteins at 
3 μmol/L final concentration for 30, 60, and 120 min. 
After incubation, cells were sedimented and resuspended 
in lysis buffer, 10% SDS and Phenol:Chloroform: isoamyl 
alcohol (IAA) and mixed with zirconia beads. RNA isola-
tion was done using the Ribopure Yeast kit (Invitrogen) 
according to manufacturer’s instructions. Samples were 
analyzed in a high sensitivity nucleic acid microfluidic 
chip using an Experion automated electrophoresis system 
(Bio- Rad, Madrid, Spain). Cellular RNA populations were 
quantified by virtual gel densitometry.
Statistical analysis
Results are reported as mean ± SD. Each mutant was com-
pared with the corresponding wild- type protein. Statistical 
analysis was performed by the paired Student’s t- test using 
STATA 11 software and IBM SPS 19 software. One- way 
analysis of variance (ANOVA) was applied.  P values <0.05 
were considered significant.
Results
Human RNases against Candida albicans
The antifungal mechanisms of action of RNase 3 and 
RNase 7 on Candida albicans were characterized through 
a variety of methodological approaches. This is the first 
direct report of the involvement of both enzymatic and 
membrane damage activities in the RNases’ antimicrobial 
activity. Single- point mutations that ablate either the protein 
catalytic (H15A) or cell- binding (W35A) activities were 
designed to evaluate the distinct protein properties.
The protein toxicity on yeast cells was first analyzed 
by plotting the colony- forming unit (CFU) reduction as 
a function of the protein concentration. Both RNases 
showed an effective protein concentration in the low mi-
cromolar range (Table 1), achieving minimal fungicidal 
concentrations (MFC100) at approximately 2 to 4 μmol/L 
(30–60 μg/mL), as evaluated in nutrient media (Sabouraud 
broth) and phosphate saline buffer (PBS) (Table 1). The 
antifungal activity was also assessed by a cell viability 
assay based on the quantification of the ATP levels that 
revealed similar IC50 values for both RNases. The calcu-
lated antifungal activity was comparable to the previously 
reported bactericidal activity (Torrent et al. 2012). 
Equivalent MFCs were achieved for low and high ionic 
strength phosphate buffers (Table S2), as previously ob-
served for RNase 3 bactericidal activity (Torrent et al. 
2012). However, the addition of increasing amounts of 
Ca2+ or NaCl to the nutrient growth media impaired 
considerably the RNases fungicidal activity (Table S2), as 
previously reported for the bactericidal action of RNase 
3 (Lehrer et al. 1989) and other AMPs (Krishnakumari 
et al. 2009). Binding to Candida cells was assessed by 
monitoring the free unbound protein after incubation at 
sublethal concentrations in PBS for 1 h at 37°C (Fig. S1). 
No binding was achieved in equivalent assay conditions 
by the homologous RNase A, used here as a non anti-
microbial reference protein.
Table 1. Antifungal activities of RNase 3, RNase 7, and mutant variants 
on Candida albicans.
Protein MFC100 (μmol/L) IC50 (μmol/L)
Sabouraud Broth PBS
RNase 7 2.5–5 2.5 1.60 ± 0.09
RNase 7- H15A 3.5–5 2.5–5 1.93 ± 0.07*
RNase 3 2.5 2.5 2.50 ± 0.01
RNase 3- H15A 5–10 5–10 3.45 ± 0.08**
RNase 3- W35A >20 >20 9.03 ± 0.52**
Minimal fungicidal concentration (MFC100) values were calculated by 
CFU counting on plated Petri dishes as described in the methodology. C. 
albicans cultures were treated with the proteins diluted in either the 
Sabouraud nutrient growth media or in a phosphate saline buffer (PBS). 
IC50, given as mean ± SD, were determined using the Bactiter- Glo™ kit 
as detailed in the Experimental Procedures. Values are averaged from 
three replicates of two independent experiments. For the comparison of 
numerical variables between wild- type and mutant, the Student’s t- test 
was used. Values of P < 0.05* and P < 0.009** are indicated.
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Additionally, RNase 3 and RNase 7 action at the cell 
plasma membrane was evaluated by assessing their ability 
to trigger the depolarization and permeabilization of the 
cell membrane (Table 2). Complementarily, studies of 
both the kinetics of the depolarization and permeabiliza-
tion activities of the enzymes were compared. Furthermore, 
a time course monitoring of the protein toxicity on the 
yeast cell population was completed using the Live/Dead® 
staining kit, where a major reduction in the cell survival 
percentage was shown after 1 h (Fig. S3).Next, we labeled 
the recombinant proteins with an Alexa Fluor fluorescent 
marker and tracked the location of the proteins in cell 
cultures, in which the cell nuclei were stained with Hoechst 
stain (Fig. S2). The protein distribution was analyzed and 
it was observed that the protein and cell signals colocal-
ized (Fig. 2). The protein internalization was also visualized 
at sublethal concentrations and short incubation times 
after removal of any remaining free protein (Fig. 2D).
A dual mode for RNases antifungal activity
The mechanism of action against C. albicans was then 
analyzed by ablating either the enzymatic activity or cell 
binding ability of the proteins. To assess the potential 
contribution of the catalytic activity of the RNases on 
their antimicrobial action, we prepared mutants of both 
RNases with defective active sites. The active site mutants 
were designed by making substitutions at His 15 within 
the active site catalytic triad (Boix et al. 1999; Huang 
et al. 2007), where His 15 is the counterpart of His 12 
in RNase A (Fig. 1) (Cuchillo et al. 2011). The histidine 
to alanine substitution almost abolished all of the protein 
enzymatic activity for both RNases (Table 4) as previously 
reported by Raines and coworkers for the RNase A- H12A 
mutant counterpart (Park et al. 2001). Additionally, the 
overall three- dimensional structure and the active site 
architecture of the mutant protein were maintained, as 
confirmed by solving the RNase 3- H15A mutant X- ray 
crystal structure (PDB ID: 4OWZ) (Fig. 1 and Table S1). 
The functional characterization of both active site mutants 
confirmed that these mutant proteins conserved their 
membrane lytic activity, showing an equivalent leakage 
activity on lipid vesicles (Table 4). Furthermore, the po-
tential contribution of the H15 residue on the proteins’ 
affinity for the cell membrane was discarded, being a 
residue poorly exposed to the protein surface (solvent 
accessible surface area, SASA, for His 15 ~ 14 Å; 4A2Y.
pdb (Boix et al. 2012a)).
Following, we compared the recombinant variants with 
ablated active sites with the wild- type proteins in yeast 
cell cultures (Table 1). The protein activities were evalu-
ated both by comparing the CFU count and assessing 
the cell viability by monitoring the ATP levels (Table 1). 
Differences between the cytotoxicities of the wild- type and 
active site mutants were observed at sublethal concentra-
tions and final incubation times. A kinetic time course 
of yeast cell viability indicated that the catalytically defec-
tive proteins showed a delay in their t50 values together 
with a lower rate of cell death at the final incubation 
time (Table 3). On the other hand, the active site muta-
tions did not interfere with the protein membrane lysis 
activity on synthetic lipid vesicles (Table 4). Notably, 
depolarization time course profiles revealed no major dif-
ferences between wild- type and active site mutant proteins 
in comparison with the membrane binding defective mutant 
(Tables 2 and 3). Additionally, there was no difference 
in the protein binding to the yeast cells for the H15A 
variant, as quantified by a fluorescence assisted cell sorting 
(FACS) assay (Fig. 3). On the other hand, by combining 
FACS analysis and propidium iodide (PI) staining, we 
also estimated the live and dead cell subpopulations, con-
firming that the membranes of the cells were not signifi-
cantly compromised at the assayed conditions (Figs. 3 
and S4).
Table 2. Cell membrane depolarization and permeabilization activities of RNases on Candida albicans.








RNase 7 165.77 ± 1.10 71.67 ± 0.1 134.56 ± 1.95 45.90 ± 0.5
RNase 7- H15A 153.96 ± 1.65* 66.54 ± 0.9 93.05 ± 1.24* 31.52 ± 0.3
RNase 3 80.07 ± 0.90 34.62 ± 0.08 104.93 ± 2.80 35.55 ± 0.4
RNase 3- H15A 67.27 ± 1.13* 29.08 ± 1.0 61.32 ± 0.63** 20.77 ± 0.2
RNase 3- W35A 28.42 ± 0.42** 12.28 ± 0.7 24.84 ± 0.25** 8.46 ± 0.6
Maximum membrane depolarization and permeabilization activities were determined at 1 μmol/L final protein concentration at final incubation time 
using the DiSC3(5) probe and Sytox
® Green, respectively, as described in Experimental Procedures. All values, given as mean ± SD, are averaged from 
three replicates of two independent experiments.
1Arbitrary fluorescence unit (AU) values are indicated for maximum membrane depolarization and permeabilization.
2The calculated percentages refer to the maximum values achieved at final incubation time, referred to the positive control (10% of Triton X- 100).
The P value were calculated using as reference each wild- type activity (*corresponds to P < 0.05 and ** to P < 0.009).
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Lastly, the potential effect of the RNases on the yeast 
intracellular RNA was assessed. Total cellular RNA was 
extracted from treated cultures and analyzed by capillary 
electrophoresis (Fig. 4A). To estimate the relative activity 
on cellular RNA, the corresponding time course of the 
decrease in rRNA subunits was evaluated by densitometry 
as a function of time (Fig. 4B). The results confirmed 
that there was a drastic reduction in the cellular RNA 
degradation rate for the active site mutants. All assays 
were carried out at sublethal conditions, as confirmed by 
a simultaneous time course monitoring of the cell culture 
population by optical density at 600 nm and CFU count-
ing. Moreover, no significant reduction in the cell viability 
at the assayed conditions was observed by the quantifica-
tion of the ATP levels during the first 15 min (Fig. S5). 
We even observed a slight increase in the ATP concentra-
tion at the very beginning of the incubation time, which 
might be attributed to a blockage of the cell protein 
synthesis machinery, probably induced by the RNase bind-
ing to cellular nucleic acids.
Complementarily, we assayed an RNase 3 mutant ver-
sion (W35A), previously reported as defective in its 
Figure 2. Confocal microscopy analysis of Candida albicans cell culture (~3 × 106 cells/mL) incubated with 1 μmol/L of RNase 3, RNase 7 and mutants 
labeled with Alexa Fluor 488 (green). (A and B) Cells were stained with Hoescht 33342 dye (blue) following the assay incubation conditions detailed 
in the Experimental Procedures section. Fluorescence and differential interference contrast (DIC) merge images were taken. Analysis was made at 2 
and 20 min after protein addition at 1 μmol/L final concentration. After protein addition, the evolution of the fluorescence signals was analyzed by 
confocal microscopy. A total of 20 cells were analyzed by regions of interest (ROIs) using the Leica TCS software. Yeast size mean was adjusted 
according to Hoescht- labeled distribution and disc image. The cell mean size was around 4.5 μm and a distance between 4.5 and 8 μm was ascribed 
to the cell environment. (A) Profiles of fluorescence intensity for Alexa Fluor 488- labeled protein (green) and C. albicans cells stained with Hoescht 
33342 (blue). Examples of fluorescence profiles are shown at 2 min and 20 min for RNase 3. (B) Bar graphs of total internal and external fluorescence 
intensity values (maximum peak) are shown. Black bar corresponds to outer fluorescence and gray and light gray bar to inner fluorescence at 2 and 
20 min, respectively. (C and D) Confocal microscopy analysis of Candida cell culture (~3 × 106 cells/mL) incubated with 1 μmol/L of RNase 3, RNase 7 
and mutants labeled with alexa fluor 488. Distribution of Alexa Fluor 488- labeled protein in treated C. albicans cells visualized by confocal microscopy, 
(C) Protein localization in yeast cells after 20 min of incubation at 37°C with labeled proteins. (D) Merged images after additional PBS washes to 
eliminate fluorescence background and free- labeled proteins. The images were taken using a Leica TCS SP5 AOBS microscope.
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protein- membrane interaction without affecting its RNase 
activity (Carreras et al. 2003; Nikolovski et al. 2006; 
Torrent et al. 2007). The present results confirm the 
key role of the surface exposed Trp (Fig. 1B) in the 
toxicity of the protein to yeast cells. The W35A mutant 
displays a two to threefold reduction in its fungicidal 
(Table 1) and membrane destabilizing activities (Table 2). 
Mostly, the abilities of RNase 3 to cause membrane 
depolarization and disruption were severely impaired 
(Table 2). Indeed, by confocal microscopy, we visualized 
how the labeled W35A mutant does not associate to 
the yeast cell surface and is not internalized (Figs. 2 
and S2). Furthermore, there was no significant rate of 
intracellular RNA cleavage, which corroborates that the 
protein has a defective internalization mechanism 
(Fig. 4).
Discussion
There is an urgent need to develop alternative antibiotics. 
Exploring the mechanisms of action of our own self- 
defense machinery is a promising strategy toward the 
design of new drugs. Human antimicrobial RNases, which 
are secreted upon infection and display a variety of  cytotoxic 
activities, provide a suitable working model. In particular, 
several members of the vertebrate RNase A family were 
previously reported to display toxicity against fungal patho-
gens, such as RNase 5 (Hooper et al. 2003), RNase 7 (Harder 
and Schroder 2002; Huang et al. 2007) or RNase 8 (Rudolph 
et al. 2006).
In this work, we have selected the two most studied 
human antimicrobial RNases, the eosinophil RNase 3 and 
the skin- derived RNase 7, which are upregulated upon 
infection (Glaser et al. 2009; Mohammed et al. 2011; Boix 
et al. 2012b; Becknell et al. 2015) and are directly im-
plicated in the host defense against fungal infections 
(Rothenberg and Hogan 2006; Rosenberg et al. 2013). 
Candida albicans was chosen here because it is a simple 
eukaryotic pathogen that provides a suitable model to 
analyze the distinct protein targets at the cellular level. 
High fungicidal activities were achieved for both RNases, 
with MFCs on the low micromolar scale (Table 1). Together 
with the analysis of the RNases’ membrane damage, we 
have followed their cell internalization and enzymatic 
 action. The present results highlight that the RNases have 
a dual mode of action. Indeed, antimicrobial RNases should 
be regarded as multifunctional proteins, combining an 
enzymatic activity and a mechanical action at the mem-
brane level, together with other described immunomodula-
tory activities (Boix and Nogués 2007; Gupta et al. 2012). 
Similar examples of multitargeted antimicrobial proteins 
are available in the literature, combining intracellular tar-
gets with a variety of immunomodulating properties 
(Hancock and Sahl 2006; Peschel and Sahl 2006; Nicolas 
2009; Haney and Hancock 2013). Unfortunately, the meth-
odological limitations and the disparity of experimental 
conditions have mostly delayed the understanding of the 
mechanism of AMPs (Nicolas 2009; Spindler et al. 2011; 
Stalmans et al. 2013). It is noteworthy that many proposed 
roles of AMPs, such as immunomodulation or intracel-
lular targeting, are only observed when working at sublethal 
assay conditions (Holm et al. 2005; Haney and Hancock 
2013).
In this context, the present results once again highlight 
the key influence of the selection of assay conditions. 
Our results indicated that the labeled protein readily 
 associated to the yeast cells at short incubation time and 
was subsequently internalized (Figs. 2 and S2). By tracking 
the cell population using a cell sorting assay combined 
Table 3. Comparison of calculated time to achieve 50% activity (t50) for membrane depolarization, membrane permeabilization, and cell survival.




Cell survival t50 (sec) Cell survival (%)
RNase 7 261.23 595.53 1397 38.2
RNase 7- H15A 288.53 698.15* 1763* 54.86**
RNase 3 251.36 490.84 2354 56.87
RNase 3- H15A 356.75* 975.5** 2965* 67.89**
All assays were carried out at 1 μmol/L final protein concentration. Depolarization was assayed using DISC3(5) dye, cell leakage by the Sytox Green 
assay and survival percentage at final incubation time (120 min) was evaluated using the Live/dead® kit. T- student was applied for comparison of 
numerical variables using as reference each activity corresponding to wild- type protein, where * corresponds to P < 0.05 and ** to P < 0.009.
Table 4. Relative enzymatic activity was determined by the spectropho-
tometric method using (Cp)4C>p substrate as described in the 
Experimental Procedures section.
Protein RNase activity (%) LUV leakage ED50 (μmol/L)
RNase 7 100 1.14 ± 0.03
RNase 7- H15A 9 1.24 ± 0.09
RNase 3 100 1.33 ± 0.71
RNase 3- H15A 0 1.44 ± 0.14
Leakage of large unilamellar vesicles (LUV) is expressed as 50% effective 
dose (ED50), given as mean ± SD, averaged from three replicates of two 
independent experiments.
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Figure 3. Analysis of Candida albicans cell culture (1 × 106 cells/mL) incubated with 1 μmol/L of protein by FACS. Cells were gated by Forward scatter 
(FSC)/Side scatter (SSC). Additionally, the incubation mixture was treated with PI to identify the dead cell population. After addition of RNase 7 (A) 
and RNase 7- H15A (B) the samples were analyzed using a FACSCalibur cytometer at 2, 5, 15 and 60 min. Dot plot diagrams of Protein Alexa Fluor 
488/PI show cell population divided in: free live cells (blue), cells with uptake protein (green), free dead cells (red), and dead cells with protein uptake 
(orange). Control corresponds to untreated cells.
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with staining of membrane compromised cells, we con-
firmed that in the assayed conditions, there was no sig-
nificant cell death (Figs. 3 and S4). The timing of events 
illustrated how cell membrane damage is only achieved 
at longer incubation times or higher protein concentra-
tions. Consequently, previous results obtained at higher 
protein concentrations attributed RNase 3 cytotoxicity 
merely to cell lysis action (Carreras et al. 2003; Torrent 
et al. 2007; Singh and Batra 2011; Torrent et al., 2010b). 
Additionally, we cannot discard other complementary 
processes, such as the RNases’ binding to nucleic acids 
and blockage of the cell protein translation machinery. 
Figure 4. Effect of RNases on Candida albicans cellular RNA. 1 mL of yeast cell suspension (~ 1 × 107 cells/mL) was treated with 3 μmol/L of each 
protein and incubated at different time intervals. Following, total RNA was extracted as described in Experimental Procedures. (A) Samples were 
analyzed by an Experion automated electrophoresis system and RNA was visualized with the Experion software. Left lane contains molecular mass 
markers, where reference base pairs are indicated. Control lane corresponds to cellular RNA from untreated cells. The RNA extraction was made at 
different time intervals up to 20 min. (B) Peak area corresponding to 18/28s subunits of rRNA of treated cells with wild- type and mutant RNases are 
shown for each incubation time.
(A)
(B)
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Indeed, a previous report on the bactericidal activity of 
RNase 7 already suggested its putative interaction with 
cellular nucleic acids (Lin et al. 2010), as reported for 
other cationic AMPs (Brogden 2005; Nicolas 2009).
Contribution of the RNase catalytic activity to the 
 cytotoxic properties within the RNase A superfamily mem-
bers remains a matter of controversy. Although we can 
find some reports on the RNase antimicrobial activity 
inhibition by either diethyl pyrocarbonate (DEPC) treat-
ment or by the proteinaceous RNase inhibitor (RI) (Abtin 
et al. 2009), the experimental results should be interpreted 
with caution. Indeed, the horseshoe- like shaped inhibitor 
structure can engulf the RNase inside its internal cavity, 
covering the cationic residues involved in the protein an-
timicrobial activity, as proposed for the RI interference of 
RNase 7 binding to LPS (Spencer et al. 2014). Similarly, 
treatment with DEPC would modify not only the catalytic 
His but other His residues exposed at the protein 
surface.
In any case, our results confirmed that not only are 
RNase 3 and RNase 7 internalized in yeast cells (Fig. 2), 
they also contribute by their enzymatic activities to the 
cell killing process Both RNase H15A variants showed 
impaired catalytic activity but retained their destabilization 
action on lipid bilayers (Table 4). Besides, both active 
site mutants retained their cell binding and internalization 
abilities (Figs. 2 and 3). On the contrary, the reduction 
in their fungicidal activity was significant (Table 1) and 
the cellular RNA degradation rates for the active site 
mutants were drastically reduced (Fig. 4).
In addition, the RNase 3- W35A defective mutant was 
used to probe the contribution of the association of the 
protein to the cell surface. Residue W35 lies at a protein 
patch involved in interactions with lipid bilayers and 
 extracellular matrix components (García- Mayoral et al. 
2010; Torrent et al. 2011a; Lien et al. 2013), proposed to 
serve as a vehicle for drug delivery (Fang et al. 2013). In 
particular, the W35 residue was identified to participate 
in the binding of LPS and glycosaminoglycans (Fan et al. 
2008; García- Mayoral et al. 2013; Pulido et al. 2013a). We 
can hypothesize that equivalent interactions may also con-
tribute to the proteins’ association with the Candida cell 
wall, which is predominantly composed of glucan com-
ponents. Indeed, common binding motifs are found for 
beta- glucan pattern recognition proteins and other 
carbohydrate- binding proteins, such as LPS and heparan 
sulfate. In particular, a shared binding motif for LPS and 
1,3- beta- glucans is involved in invertebrate innate immunity 
(Iwanaga and Lee 2005).
Our studies on Candida also highlighted the require-
ment of the Trp residue for membrane damage, protein 
internalization, and cellular RNA degradation (Figs. 2, 4 
and S2; Table 2). Interestingly, cell internalization is easily 
achieved by other members of the vertebrate RNase A 
family (Haigis and Raines 2003; Benito et al. 2008; Chao 
and Raines 2011; Sundlass et al. 2013). As an example, 
the cellular trafficking and ribonucleolytic activities of 
human RNase 5 are essential for its angiogenic action 
(Thiyagarajan et al. 2012). The antimicrobial RNases might 
also be regarded as “cell penetrating proteins.” Indeed, 
the intracellular routing of secretory RNases could promote 
their physiological role in innate immunity; a process that 
can be regulated by the presence of the ribonuclease in-
hibitor (RI), which is ubiquitous in the cytosol of mam-
malian cells (Lomax et al. 2014). Interestingly, very recent 
results on the down regulation of RI during uropathogen 
infections suggests a direct mechanism that facilitates the 
antimicrobial activity of RNases when required (Spencer 
et al. 2014).
Understanding the determinants that can assist protein 
translocation without inducing any cell damage is desired 
for the design of alternative targeted drugs. Although many 
cationic and amphipathic AMPs are classified as cationic 
penetrating peptides (CPPs) (Brogden 2005; Nicolas 2009; 
Stalmans et al. 2013), most CPP behavior has only been 
tested against mammalian cells (Last et al. 2013), but few 
peptides have been described against putative eukaryote 
pathogens (Do et al. 2014). Thus, the study of CPPs in 
yeast is an emerging field that offers promising biotech-
nological applications (Nekhotiaeva et al. 2004; Holm et al. 
2005; Mochon and Liu 2008; Marchione et al. 2014).
In conclusion, the observed antimicrobial effective doses 
for both RNases were found to be in the low micromolar 
range, which is promising in the design of antifungal 
agents. Hence, the human RNases secreted from blood 
and epithelial cells, which combine membrane lytic and 
enzymatic RNase activities, could work as first line safe-
guard sentinels. In a wider context, the vertebrate secreted 
RNases could contribute to the protection of a variety 
of body fluids, from seminal to placental fluids, tears, or 
even milk (D’Alessio et al. 1991; Leonardi et al. 1995; 
Harris et al. 2010). Indeed, a nonspecific RNA degrada-
tion activity would represent one of the quickest and 
most effective ways of targeting pathogen viability. We 
can speculate that secreted RNases may exert a direct 
host defense role by the removal of pathogenic RNA, 
both within infected cells and resident at the extracellular 
matrix (Gupta et al. 2012). Therefore, as innate immunity 
effectors, human RNases are proving to be an ideal system 
for the design of nonantigenic nanodelivery tools to fight 
invading pathogens. AMPs offer the opportunity of find-
ing new antifungal agents, as few effective antifungal 
peptides are currently available (Swidergall and Ernst 2014; 
Tsai et al. 2014). Thus, the study of human antimicrobial 
RNases provide a promising model for the design of new 
applied therapies against fungal infections.
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